An etanercept biosimilar is equivalent to its reference biologic in terms of efficacy at week 24 and has a similar safety profile and lower immunogenicity, a phase III study shows. The double-blind, parallel-group, multicentre study randomised 596 patients with moderate to severe RA to either the etanercept (ETN) biosimilar (SB4) or ETN. The ACR20 response rate ...
ETN biosimilar reaches therapeutic equivalence
7 Jul 2015